159 related articles for article (PubMed ID: 24988879)
1. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Caffo O; De Giorgi U; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Macrini S; Messina C; Giordano M; Alesini D; Zustovich F; Fraccon AP; Vicario G; Conteduca V; Maines F; Galligioni E
BJU Int; 2015 May; 115(5):764-71. PubMed ID: 24988879
[TBL] [Abstract][Full Text] [Related]
2. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
[TBL] [Abstract][Full Text] [Related]
3. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
Van Praet C; Rottey S; Van Hende F; Pelgrims G; Demey W; Van Aelst F; Wynendaele W; Gil T; Schatteman P; Filleul B; Schallier D; Machiels JP; Schrijvers D; Everaert E; D'Hondt L; Werbrouck P; Vermeij J; Mebis J; Clausse M; Rasschaert M; Van Erps J; Verheezen J; Van Haverbeke J; Goeminne JC; Lumen N
Urol Oncol; 2016 Jun; 34(6):254.e7-254.e13. PubMed ID: 26850781
[TBL] [Abstract][Full Text] [Related]
5. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
[TBL] [Abstract][Full Text] [Related]
6. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
8. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
10. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
Sella A; Sella T; Peer A; Berger R; Frank SJ; Gez E; Sharide D; Hayat H; Hanovich E; Kovel S; Rosenbaum E; Neiman V; Keizman D
Clin Genitourin Cancer; 2014 Dec; 12(6):428-32. PubMed ID: 25066221
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
Stuyckens K; Saad F; Xu XS; Ryan CJ; Smith MR; Griffin TW; Yu MK; Vermeulen A; Nandy P; Poggesi I
Clin Pharmacokinet; 2014 Dec; 53(12):1149-60. PubMed ID: 25204404
[TBL] [Abstract][Full Text] [Related]
15. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
[TBL] [Abstract][Full Text] [Related]
18. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
Procopio G; Grassi P; Testa I; Verzoni E; Torri V; Salvioni R; Valdagni R; de Braud F
Am J Clin Oncol; 2015 Oct; 38(5):479-82. PubMed ID: 24064757
[TBL] [Abstract][Full Text] [Related]
19. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]